Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due t...

Full description

Bibliographic Details
Main Authors:	Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Endocrinology
Subjects:	ruxolitinib energy expenditure weight gain intolerance leptin
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1141029/full

Similar Items

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
by: Martina Barone, et al.
Published: (2020-01-01)

JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review
by: Faranaz Atschekzei, et al.
Published: (2024-08-01)

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report
by: Colomba Claudia, et al.
Published: (2012-10-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

Treatment Strategies Used in Treating Myelofibrosis: State of the Art
by: Massimo Martino, et al.
Published: (2024-10-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
by: Vera Stoeva, et al.
Published: (2023-07-01)

Trends in overall mortality among US veterans with primary myelofibrosis
by: Tsewang Tashi, et al.
Published: (2023-01-01)

NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin
by: Magalie Haissaguerre, et al.
Published: (2018-05-01)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
by: Daniele Cattaneo, et al.
Published: (2021-11-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01)

Recent progress of JAK inhibitors for hematological disorders
by: Keita Kirito
Published: (2023-07-01)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
by: Anna Hirano, et al.
Published: (2017-01-01)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
by: Meltem Aylı, et al.
Published: (2015-05-01)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
by: Giacomo Coltro, et al.
Published: (2023-04-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
by: Rosa Ayala, et al.
Published: (2023-05-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
by: Camille Keenan, et al.
Published: (2021-02-01)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
by: Annalisa Marcuzzi, et al.
Published: (2022-03-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
by: Antoine El Kik, et al.
Published: (2024-01-01)

Predictors of weight and waist gain in US South Asians: Findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study
by: Sujatha Seetharaman, et al.
Published: (2024-09-01)

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
by: Miguel Mansilla-Polo, et al.
Published: (2024-05-01)

Effect of tuberculosis treatment on leptin levels, weight gain, and percentage body fat in Indonesian children
by: Maria Mexitalia, et al.
Published: (2017-04-01)

Exploring the Relationship Between Maternal Circulating Hormones and Gestational Weight Gain in Women Without Obesity: A Cross-Sectional Study
by: Lappas M, et al.
Published: (2020-06-01)

Myelofibrosis treatment history and future prospects
by: Amr Ghit
Published: (2022-11-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
by: Hans Michael Kvasnicka, et al.
Published: (2018-03-01)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
by: Timothy Devos, et al.
Published: (2022-01-01)

Leptin receptor neurons in the dorsomedial hypothalamus are key regulators of energy expenditure and body weight, but not food intake
by: Kavon Rezai-Zadeh, et al.
Published: (2014-10-01)

The Gut Microbiome of Preterm Infants Treated With Aminophylline Is Closely Related to the Occurrence of Feeding Intolerance and the Weight Gain
by: Wei Shen, et al.
Published: (2022-05-01)

JAK inhibitors in systemic juvenile idiopathic arthritis
by: Tingyan He, et al.
Published: (2023-04-01)

Incidence of blast phase in myelofibrosis according to anemia severity
by: Barbara Mora, et al.
Published: (2023-08-01)

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
by: Natalie Frede, et al.
Published: (2023-01-01)

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
by: Chen X, et al.
Published: (2023-06-01)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
by: Moshe Talpaz, et al.
Published: (2018-08-01)

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer
by: Karen Geoffroy, et al.
Published: (2024-09-01)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
by: Novella Pugliese, et al.
Published: (2019-06-01)